Maxim Group Maintains Buy On IsoRay Following Fiscal Year 2014 Results
In a report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on IsoRay Inc (NYSE:ISR) with a $5 price target, following the company’s June 2014 year-end results.
Kolbert said, “We spoke with CEO Dwight Babcock and reviewed the evidence that is building for Cesium-131. Management is seeing interest building in the treatment of brain cancers (meningiomas, brain metastases, and glioblastomas), lung cancer (NSCLC), gynecological cancer, prostate cancer, head and neck cancer, and liquid Cesium-131 in the GliaSite Radiation Therapy System, used to treat brain cancers.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 8.9% and a 47.1% success rate. Kolbert has an -42.3% average return when recommending ISR, and is ranked #332 out of 3314 analysts.